drugset / Trial / NCT00549146

Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease

NCT00549146

Phase 3 Completed 290 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

Relatively little information is available about the effects of salmeterol/fluticasone combination and fluticasone alone in COPD patients with a partial reversible pulmonary obstruction. The purpose of this study is to compare the effects of salmeterol/fluticasone combination with fluticasone alone delivered via Diskus/ACCUHALER inhaler in subjects with COPD on lung function over a 1 year period.

Timeline

Start
2003-11
Primary completion
2006-04
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 250 ug Inhaled
Subject Fluticasone propionate Other / unclassified 500 ug Inhaled
Subject Salmeterol Other / unclassified 50 ug Inhaled